| Autor: |
Aylin Yilmaz, Arash Izadkhashti, Richard W. Price, Patrick W. Mallon, Marc De Meulder, Philip Timmerman, Magnus Gisslén |
| Zdroj: |
AIDS Research & Human Retroviruses; Apr2009, Vol. 25 Issue 4, p457-461, 5p |
| Abstrakt: |
AbstractDarunavir is the most recently licensed protease inhibitor currently used in treatment-experienced HIV-infected individuals. Our objective was to determine darunavir concentrations in cerebrospinal fluid (CSF) and plasma in subjects receiving antiretroviral treatment regimens containing ritonavir-boosted darunavir. Darunavir concentrations were determined by liquid chromatography tandem mass spectrometry in 14 paired CSF and plasma samples from eight HIV-1-infected individuals. The lower limit of quantification was 5.0 ng/ml. All of the 14 CSF samples had detectable darunavir concentrations with a median darunavir concentration of 34.2 ng/ml (range 15.9–212.0 ng/ml). The median (range) plasma darunavir concentration was 3930 (1800–12900) ng/ml. All CSF samples had detectable darunavir concentrations. Most of them exceeded or were in the same range as levels needed to inhibit replication of wild type virus, making it probable that darunavir, at least to some extent, contributes to the suppression of HIV replication in the central nervous system. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
